FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Epix touts data on pulmonary hypertension drug

Shares of Epix Pharmaceuticals were buoyed this morning by positive data from a mid-stage study of a drug designed to reduce high blood pressure in the pulmonary artery. The trial of PRX-08066 involved 71 patients with pulmonary hypertension associated with COPD. Lexington, MA-based Epix also reported that its losses ballooned in the second quarter due to swelling R&D costs.

- see the release for more

Related Articles:
Epix shares soar on $1.2B pact with GSK. Report
Epix anxiety drug fails in late-stage trial. Report
Epix to buy Predix in $90M merger. Report

More stories about pharmaceuticals   GlaxoSmithKline   Drug Trials   blood pressure   COPD   Epix  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 39 + 40?
To combat spam, please solve the math question above.